Zeping Chen
陈泽平
Zeping Chen is the founder and CEO of Yan Yin Tech (衍因科技), a biotech company developing AI-powered tools for cell and gene therapy R&D . Under his leadership, the company has partnered with HEC Pharm on strategic AI collaboration , launched China's first CRISPR gene design tool with ZhuanMa Bio , and formed partnerships with Shanghai Technology Exchange and Xinchao Data . Chen has also spoken on how AI and digitalization can empower innovation in cell and gene therapy development . The company's work has been featured in Qiming Venture Partners' portfolio updates throughout 2025 .
AI-generated — may contain errors, please verify.
Coverage
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Vol. 35, 2025
Staying with you through milestone moments at Qiming Venture Partners portfolio companies
Qiming Venture Partners Weekly | Portfolio Company Updates Vol. 34, 2025
Tracking milestone moments with you for Qiming Venture Partners' portfolio companies
Qiming Portfolio Company Yanyin Technology Partners with HEC Pharm on Strategic AI Collaboration
The two parties will engage in in-depth collaboration on AI agent R&D, using the AI translation agent project as a starting point to develop solutions covering core scenarios including experimental design and IND filing, as well as AI laboratory automation robotics. Together, they will explore the deep application of AI technology across the full drug discovery and development pipeline, accelerating the globalization strategy of East Sunshine Pharmaceutical.
Qiming Weekly | Qiming Venture Partners Portfolio News & Updates Vol. 33, 2025
Celebrating milestone moments with you at Qiming Venture Partners' portfolio companies
Qiming Venture Partners Portfolio Companies YanYin Technology and ZhuanMa Bio Launch China's First CRISPR Gene Design Tool
The two parties will jointly develop a next-generation CRISPR design application platform, deeply integrating Zuanma Biotech's cutting-edge gene editing technology with YanYin AI's cloud-based R&D platform. This collaboration will deliver unprecedented convenience, precision, and efficiency to CRISPR gene editing users worldwide, dramatically streamlining the design and analysis workflows for gene editing experiments.
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Roundup Vol. 13, 2025
Following Qiming Venture Partners' portfolio companies' milestone moments with you
